UPCC 15820: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of this study is to see if niraparib added to a standard treatment (abiraterone acetate and prednisone) will work better than abiraterone acetate and prednisone alone in treating men with metastatic prostate cancer with specific genetic changes. Eligible subjects will be men with metastatic prostate cancer.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Medical Research
• Age: - 99 Years
• Gender: All